Compare ADMA Biologics Inc (ADMA) vs STMicroelectronics NV (STM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs STMicroelectronics NV — how do they compare? ADMA Biologics Inc trades at $9.18 (market cap $2.13B), while STMicroelectronics NV trades at $68.62 (market cap $59.25B). The key difference: STMicroelectronics NV is far larger — about 27.8× ADMA Biologics Inc's market cap, and STMicroelectronics NV pays a 0.54% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | STM | |
|---|---|---|
Market Cap | $2.13B | $59.25B |
Sector | Health | Financials |
52-Week High | $20.38 | $79.91 |
52-Week Low | $7.60 | $21.20 |
Enterprise Value | $2.20B | $57.46B |
Dividend Yield | — | 0.54% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
STM trades at $67.28, down 1.57% today, with a neutral technical signal and mixed earnings history. The company shows strong cash flow from operations at $2.15B in 2025 and maintains a solid balance sheet with $6.18B cash. Recent news highlights growth in AI, automotive, and industrial segments, including new product launches like the VL53L9 LiDAR module. Analyst consensus is a Buy with a $72.33 price target, indicating potential upside from current levels.
Outlook is cautiously optimistic given STM's strategic positioning in high-growth semiconductor markets, but high valuation ratios (P/E 446.19) and recent earnings misses pose risks. Revenue decline from $17.3B in 2023 to $11.8B in 2025 requires monitoring, though cost control and innovation in edge AI and automotive chips offer long-term opportunities amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About STMicroelectronics NV
A merger between Italian firm SGS Microelettronica and the nonmilitary business of Thomson Semiconductors in France formed STMicroelectronics in 1987. STMicro is a leader in a variety of semiconductor products, including analog chips, discrete power semiconductors, microcontrollers, and sensors. STMicro is an especially prominent chip supplier into the industrial and automotive industries.
Read more on STM →
